Cue Biopharma, Inc. (CUE)
28.74
+0.74
(+2.64%)
USD |
NASDAQ |
Sep 11, 16:00
28.83
+0.09
(+0.31%)
Pre-Market: 20:00
Cue Biopharma Gross Profit Margin (Quarterly) : 99.54% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 99.54% |
| March 31, 2026 | 98.65% |
| December 31, 2025 | 99.69% |
| September 30, 2025 | 96.32% |
| June 30, 2025 | 96.61% |
| March 31, 2025 | -109.3% |
| December 31, 2024 | 0.00% |
| September 30, 2024 | 73.65% |
| June 30, 2024 | 67.42% |
| March 31, 2024 | 50.55% |
| December 31, 2023 | 53.27% |
| September 30, 2023 | 59.19% |
| June 30, 2023 | 38.64% |
| March 31, 2023 | -370.6% |
| December 31, 2022 | -283.6% |
| September 30, 2022 | -692.6% |
| June 30, 2022 | -1.66K% |
| Date | Value |
|---|---|
| March 31, 2022 | 77.10% |
| December 31, 2021 | 0.00% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
| December 31, 2020 | 0.00% |
| September 30, 2020 | 0.00% |
| June 30, 2020 | 0.00% |
| March 31, 2020 | 0.00% |
| December 31, 2019 | 0.00% |
| September 30, 2019 | 0.00% |
| June 30, 2019 | 0.00% |
| March 31, 2019 | 0.00% |
| December 31, 2018 | 0.00% |
| September 30, 2018 | 0.00% |
| June 30, 2018 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Nurix Therapeutics, Inc. | 57.43% |
| Monte Rosa Therapeutics, Inc. | 78.69% |
| Xilio Therapeutics, Inc. | 98.23% |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -1.00K% |
| Return on Assets | -463.4% |
| Return on Invested Capital | -732.6% |
| Profit Margin (Quarterly) | -1.94K% |
| Operating Margin (Quarterly) | -1.11K% |
| Return on Net Operating Assets | -2.11K% |